[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN113574058A - 吲哚类大环衍生物、其制备方法及其在医药上的应用 - Google Patents

吲哚类大环衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN113574058A
CN113574058A CN202080021819.XA CN202080021819A CN113574058A CN 113574058 A CN113574058 A CN 113574058A CN 202080021819 A CN202080021819 A CN 202080021819A CN 113574058 A CN113574058 A CN 113574058A
Authority
CN
China
Prior art keywords
compound
groups
group
cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080021819.XA
Other languages
English (en)
Other versions
CN113574058B (zh
Inventor
张晓敏
费洪博
贺峰
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN113574058A publication Critical patent/CN113574058A/zh
Application granted granted Critical
Publication of CN113574058B publication Critical patent/CN113574058B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本公开涉及吲哚类大环衍生物、其制备方法及其在医药上的应用。具体而言，本公开涉及一种通式(I)所示的吲哚类大环衍生物、其制备方法及含有该衍生物的药物组合物以及其作为治疗剂，特别是作为MCL‑1抑制剂的用途，和其治疗肿瘤、自身免疫性疾病或免疫系统疾病的用途，其中通式(I)的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202080021819.XA 2019-04-30 2020-04-29 吲哚类大环衍生物、其制备方法及其在医药上的应用 Active CN113574058B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910363884X 2019-04-30
CN201910363884 2019-04-30
PCT/CN2020/087671 WO2020221272A1 (zh) 2019-04-30 2020-04-29 吲哚类大环衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN113574058A true CN113574058A (zh) 2021-10-29
CN113574058B CN113574058B (zh) 2024-04-16

Family

ID=73028756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080021819.XA Active CN113574058B (zh) 2019-04-30 2020-04-29 吲哚类大环衍生物、其制备方法及其在医药上的应用

Country Status (3)

Country Link
CN (1) CN113574058B (zh)
TW (1) TW202106693A (zh)
WO (1) WO2020221272A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112204036B (zh) 2019-01-23 2022-12-27 苏州亚盛药业有限公司 作为mcl-1抑制剂的大环稠合的吡唑
JP2023553719A (ja) 2020-12-17 2023-12-25 ヤンセン ファーマシューティカ エヌ．ベー． Ｍｃｌ－１阻害剤としての分岐大環状４－（ピラゾール－５－イル）－インドール誘導体
WO2022251247A1 (en) * 2021-05-28 2022-12-01 Zeno Management, Inc. Macrocyclic compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743224A (zh) * 2007-04-16 2010-06-16 雅培制药有限公司 7-取代的吲哚mcl-1抑制剂
CN109071566A (zh) * 2016-04-22 2018-12-21 阿斯利康(瑞典)有限公司 用于治疗癌症的大环mcl-1抑制剂
TW201904976A (zh) * 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Ｍｃｌ-１抑制劑及其使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3781570A4 (en) * 2018-11-22 2021-06-02 Ascentage Pharma (Suzhou) Co., Ltd. MACROCYCLIC INDOLES SERVING AS MCL-1 INHIBITORS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743224A (zh) * 2007-04-16 2010-06-16 雅培制药有限公司 7-取代的吲哚mcl-1抑制剂
CN109071566A (zh) * 2016-04-22 2018-12-21 阿斯利康(瑞典)有限公司 用于治疗癌症的大环mcl-1抑制剂
TW201904976A (zh) * 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Ｍｃｌ-１抑制劑及其使用方法

Also Published As

Publication number Publication date
CN113574058B (zh) 2024-04-16
WO2020221272A1 (zh) 2020-11-05
TW202106693A (zh) 2021-02-16

Similar Documents

Publication Publication Date Title
CN112533929B (zh) 吲哚类大环衍生物、其制备方法及其在医药上的应用
TW202110837A (zh) 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
TW202128668A (zh) 并環類衍生物、其製備方法及其在醫藥上的應用
TW202321263A (zh) 磺醯胺衍生物、其製備方法及其在醫藥上的應用
TW202317564A (zh) Cdk2抑制劑及其製備方法和用途
WO2022247816A1 (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
CN114423760B (zh) 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
KR20240089594A (ko) 질소 함유 테트라시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용
CN113574058A (zh) 吲哚类大环衍生物、其制备方法及其在医药上的应用
WO2022017365A1 (zh) 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用
WO2022148358A1 (zh) 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用
CN113518779A (zh) 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
CN112574212B (zh) 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN111205309B (zh) 吲哚类大环衍生物、其制备方法及其在医药上的应用
WO2021104413A1 (zh) 稠合吡啶环衍生物、其制备方法及其在医药上的应用
TW202246271A (zh) 氮雜芳基化合物、其製備方法及應用
CN110964034B (zh) 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
CN111187277B (zh) 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
CN111349105B (zh) 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN110218218B (zh) 苯并呋喃类衍生物、其制备方法及其在医药上的应用
WO2024067463A1 (zh) 苯并[7]环烯类衍生物、包含其的药物组合物及其医药用途
HK40045551A (zh) 吲哚类大环衍生物、其制备方法及其在医药上的应用
TW202345811A (zh) 吲唑類化合物、其製備方法及其在醫藥上的應用
WO2024217481A1 (zh) Egfr降解剂、其药物组合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant